In recent years, more and more studies have shown that microRNAs (miRNAs) play a key role in many important biological processes. Dysregulation of miRNAs can lead to a variety of diseases like cancers, thus predicting potential miRNA-disease associations is important for understanding drug development and disease pathogenesis, diagnosis and treatment. It is known that experimental methods to validate miRNA-disease associations typically involve miRNA knockout or knockdown, which is time and labor-intensive. As a result, computational models have been developed to predict unknown miRNA-disease associations from available information related to miRNAs, diseases, genes, and so on. However, their performances are yet to be improved. Noticing that appropriately combining multiple datasource is usually helpful for improving prediction accuracy, we have developed IMDAILM: Inferring miRNA-Disease Association by integrating lncRNA and miRNA data, a low-rank matrix completion model integrating miRNA, long noncoding RNA (lncRNA) and disease information to predict miRNA-disease associations. Specifically, the miRNA-disease association network and the lncRNA-disease association network are fused to form a new heterogeneous network consisting of 3 types of nodes representing miRNAs, lncRNAs and diseases. In addition, a negative sample inference method was proposed to infer unrelated miRNA-disease pairs. Based on both heterogeneous network and negative samples, a low-rank matrix completion model is proposed and solved. In practice, IMDAILM achieved an area under the curve (AUC) of 0.8884 for predicting miRNAs associated with diseases under the 5-fold cross-validation (CV), outperforming a few recent methods. IMDAILM also yielded an AUC of 0.8870 for predicting both lncRNAs and miRNAs associated with diseases. In addition, the 5-fold CV results indicate that IMDAILM is also superior to other methods in predicting miRNAs associated with isolated diseases. Finally, we confirmed a few novel predicted miRNAs associated with specific diseases like lung cancers by literature mining. In summary, the integration of lncRNA information into a matrix completion framework contributes to the prediction of miRNA-disease associations.
involved in cell growth, immune response, cell proliferation and differentiation, cell development, cell cycle regulation, apoptosis and other biological processes [7] , [8] .
There are a lot of evidences that miRNA abnormalities can lead to a variety of human diseases, especially cancers. Therefore, the identification of disease-related miRNAs is extremely important for studying the pathogenesis of diseases at the molecular level, as well as for the diagnosis, treatment and prevention of diseases [9] , [10] . In recent years, due to the high cost and labor intensity in experimental methods to identify disease-related miRNAs, the use of computational tools to predict disease-related miRNAs has become the focus of attention in the field of biology. With more and more biological data accumulated for miRNAs and diseases, effective computational methods can provide theoretical basis for experimental studies. At present, the existing computing methods mainly include machine learning-based algorithms and network-based algorithms.
In machine learning-based methods, they are usually assumed that similar miRNAs tend to cause the same disease or closely related diseases [11] . For example, Jiang et al. proposed a classification method based on support vector machine (SVM) by integrating various miRNA features to distinguish related miRNAs (positive samples) from unrelated miRNAs (negative samples) for specific diseases [12] . Xu et al. proposed a method for predicting miRNA-disease associations by enhancing the function of miRNA target defect network [13] . Zeng et al. proposed two multipath methods for predicting disease-related genes based on genedisease heterogeneity network to predict miRNA-disease associations [14] . Xiao et al. proposed a non-negative matrix decomposition method for graph regularization, and achieved good results in the cross-validation analysis [15] . Chen et al. proposed a novel miRNA-disease association prediction model (ELLPMDA) by integrating ensemble learning and link prediction to infer potential miRNA-disease associations [16] . More recently, Chen et al. proposed EDTMDA by fusing multiple basic classifiers to infer novel miRNA-disease associations, which achieves a good prediction accuracy [17] . In addition, Xuan et al. developed a new method MDAPred based on nonnegative matrix factorization to predict the miRNA association of candidate diseases, which integrated the projection of miRNA, disease, miRNA family, cluster and other information in the low-dimensional feature space [18] . However, machine learning-based algorithms face difficulties in retrieving negative samples, which may reduce their prediction performance.
In contrast, network-based methods typically calculate miRNA-disease associations by measuring random walk on a given miRNA and disease network. For example, Gu et al. proposed a network consistent projection algorithm, which combined the known miRNA-disease associations with the functional similarity of miRNAs to predict the miRNA-disease associations [19] . By constructing miRNA networks derived from miRNA-related diseases, Xuan et al. integrated the similarity between nodes, prior information of nodes and local topological structure to establish a new method based on random walk to predict potential miRNA candidates for diseases with known related miRNAs [20] . Liu et al. first integrated multi-level disease and miRNA information to calculate the similarity between diseases and miRNAs, based on which to construct a heterogeneous miRNA-disease network. A random walk with restart was then traveled on the network to predict new miRNAdisease associations [21] . Chen et al. proposed a random walk with restart on the miRNA-disease association network (RWRMDA), which constructed the miRNA-miRNA functional network through general network similarity measurement to predict the unknown miRNA-disease association. However, the method failed to link miRNA with ''isolated diseases'' [22] . In addition, Chen and Zhang proposed a method called NetCBI, in which a global heterogeneous network was constructed by integrating miRNA similarity network, disease similarity network and known miRNAdisease association network. Although NetCBI can predict miRNAs associated with isolated diseases, its prediction performance was poor [23] . Similarly, Xuan et al. proposed an algorithm named HDMP to predict can didate miRNAs for a given disease by combining the functional similarity and characteristics of miRNAs [24] . However, HDMP ignored the network topology and only considers the k most similar neighbors in the candidate set. Chen et al. developed a method Bipartite Network Projection for MiRNA-Disease Association prediction (BNPMDA), which combined bipartite network recommendation and known miRNA-disease associations [25] . However, BNPMDA is unsuitable for the prediction of diseases without any known associated miRNAs.
It is known that miRNAs and lncRNAs sometimes cooperatively affect a few diseases. The postulated functional interactions between miRNA and lncRNA have been elucidated through the researchers' attempts [26] . Thus, it might be helpful to predict miRNA-disease association by combining lncRNAs information. In this study, we proposed a method called Inferring miRNA-Disease Association by integrating lncRNA and miRNA data (IMDAILM). Specifically, IMDAILM first integrated miRNA-disease association network and lncRNA-disease association network. And then we construct a mapping network to project the bipartite miRNA-disease association to miRNA-miRNA association or disease-disease association. Negative miRNA-disease associations were inferred based on the mapping network. After that, the lncRNA+miRNA-disease and miRNA-disease association prediction were formulated as two low-rank matrix completion problems. The lncNRA+miRNAs similarity and diseases similarity were used as regularization information, and an alternating gradient descent method was used to solve the problems. We first predicted the relationship between lncRNA+miRNA and disease, and then only predicted miRNA-disease associations. The results were compared with other most advanced algorithms. 
II. MATERIALS AND METHODS
An overview of IMDAILM is shown in Fig.1 , which mainly consists of six steps: (I) Integrate lncRNA-disease association network and miRNA-disease association network; (II) Calculating the semantic similarity between disease; (III) Calculating the functional similarity between lncRNA+miRNAs; (IV) Construct bipartite graph and inferring negative samples from the graph; (V) A low-rank matrix model of similarity between lncRNA+miRNAs and disease was constructed. (VI) Solve the model by an alternating gradient descent method.
A. miRNA-DISEASE ASSOCIATIONS
We downloaded known human miRNA-disease association data from the HMDD V2.0 database [27] . After downloading these data and sorting them out, we obtained 5430 experimentally verified human miRNA-disease associations, including 383 diseases and 495 miRNAs.
B. lncRNA-DISEASE ASSOCIATIONS
The known human lncRNA-disease association data used in this study were retrieved from the lncRNADisease database [28] . After collating and standardizing the downloaded data, we obtained 352 experimentally verified human lncRNA-disease associations, involving 190 diseases and 156 lncRNAs.
C. lncRNA+miRNA-DISEASE ASSOCIATIONS
We constructed an association network by fusing lncRNAdisease and miRNA-disease data. Let NDA represent its adjacency matrix. Then, the columns of NDA represent diseases.
And the rows of NDA represent lncRNA+miRNA with the first 156 rows represent lncRNAs and the remaining 495 rows represent miRNAs. If lncRNA+miRNA(i) is related to disease(j), then NDA(i, j) = 1, and NDA(i, j) = 0 otherwise. That is:
has association with disease (j) 0, if lncRNA + miRNA (i) has no association with disease (j)
After merging the duplicated diseases in the columns, we finally obtained an adjacency matrix with 651 rows and 535 columns.
D. MEASURING DISEASE SIMILARITY AND lncRNA+miRNA SIMILARITY 1) DISEASE SEMANTIC SIMILARITY
We used the MeSH downloaded from the National Library of Medicine to construct directed acyclic graphs (DAGs) and calculate the similarity of two diseases. The DAG of disease d includes not only the ancestor nodes of d and d itself, but also the directly edges from the parent node to the child nodes.
represents d k consists of its own set of ancestor nodes, and E(d k ) represents the directly edges of the parent node to the child nodes. The corresponding set of edges. For any disease k in DAG (d k , T (d k ), E(d k )). We can use the following formula to calculate the semantic contribution of disease k to disease d k :
is the semantic contribution factor. In this study, we set = 0.5. The above formula indicates that the contribution of the disease to its semantic value is 1. And semantic contribution decreased with the increase of the distance between disease k and other diseases. Then, we define the semantic similarity between d(i) and d(j) as follows:
2) LncRNA+miRNA FUNCTIONAL SIMILARITY Studies have shown that the functional similarity of two miR-NAs or lncRNAs can be roughly estimated by their similarity in related diseases, because similar miRNAs or lncRNAs are often associated with similar diseases [29] , [30] . Therefore, similar methods as Sun et al were used to measure the functional similarity between two lncRNAs+miRNAs. Since miRNA and lncRNA were combined in this study, miRNA and lncRNA were collectively referred to as ncRNA in the calculation of functional similarity. We calculate the functional similarity between the two ncRNAs here. For any two ncRNAs n i and n j , let D i = d i k |1 ≤ k ≤ m} and D j = d j l |1 ≤ l ≤ n} are sets of diseases associated with n i and n j respectively. In order to calculate the functional similarity of two ncRNAs, the semantic similarity between a disease d and a disease set D was first defined as
Then, the functional similarity between n i and n j is calculated as follows:
The interaction between lncRNA+miRNA and disease form a bipartite graph ( Fig.2(c) ), and we use the lncRNA+miRNAdisease bipartite graph to infer negative samples. Let G = (N , D, E) be a bipartite graph in which N = {n 1 , n 2 , · · · , n m } and D = {d 1 , d 2 , · · ·d n are the set of lncRNA+miRNA and disease, respectively. E is the set of interactions between N and D.
E} is the set of diseases related to n i , that is, n i and n j are connected if they are associated with the same disease. For given bipartite graph
is an uncorrelated node pair projected by N in graph G. We can define uncorrected nodeto-D projections in the same way. Uncorrected node pairs are usually used as negative samples. Then, the adjacency matrix of B adopts the following block off-diagonal form:
F. LOW RANK MATRIX COMPLETION ALGORITHM
In the adjacency matrix, 0 indicates that lncRNA+miRNA is unrelated to the disease or represents missing values, and our purpose is to find and infer these missing values. Therefore, given a negative sample, we modify the adjacency matrix. Given that the relevant sample (positive sample) is 1, the predicted negative sample (uncorrected node pair) is modified to 10 −30 , and all other values are unknown (or missing). Then, we use the low-rank matrix completion algorithm to infer the missing value by assuming low-rank B. The process is as follows:
The symbols in the formula represent the following meanings:
, N is the lncRNA+miRNAs similarity matrix, we add the restriction N ij X i − X j 2 to explicitly state the hypothesis that similar lncRNA+miRNAs will have similar disease junction patterns. Thus, if N ij is large, i.e. lncRNA+miRNAs n i and n j are more similar, then X i − X j will be forced to be small. In order to clearly state that similar diseases will have similar assumptions about the ncRNA connection pattern, we add the last restriction. In addition, in the formula, X i and X j represent the i th and j th row of X , X T i and X T j denote the i th and j th column of X respectively. α 1 , α 2 , α 3 are the regularization parameters. fix U (t) and V (t) , calculate a matrix (t) to minimize Eq. (6);
; Repeat the above process until the difference between (t) obtained by the k th and (k + 1) th iteration is less than 10 −7 , i.e. (t,k+1) − (t,k) ≤ 10 −7 .
Next, we use an alternating gradient descent method (AGD) to solve the optimization problem of equation (6).
Where the solution of (t) can be obtained iteratively by follows:
∇U and ∇V are the gradients of the matrices U and V , respectively. Where
In order to evaluate the prediction performance of IMDAILM, we first applied our method to the known lncRNA+miRNAdisease associated data NDA and used the 5-fold CV method to evaluate its performance. The specific process is as follows: all known lncRNA+miRNA-disease associations were randomly divided into 5 uncrossed sites with equal size. We use one of the parts as a test sample for prediction, and the other four parts of the sample as training data to build a predictive model. This process is repeated 5 times and ends when all samples are predicted once. According to different thresholds, the receiver operating characteristic (ROC) curve was drawn for performance evaluation by calculating true positive rate (TPR, sensitivity) and false positive rate (FPR, 1-specificity). Sensitivity refers to the percentage of positive test samples higher than the given threshold. Specificity refers to the percentage of candidate samples whose sequencing is below a given threshold. Then, the ROC curve can be drawn according to TPR and FPR. The area under the ROC curve was calculated and the performance of the model was evaluated numerically. Area under ROC curve is defined as AUC. AUC = 0.5 represents completely randomly prediction, and AUC = 1 represents completely prediction. Obviously, this area is less than 1. Since the ROC curve is generally above the line y = x, the value range of AUC is between 0.5 and 1. The AUC value is used as the evaluation standard, because in many cases, ROC curve cannot directly indicate which classifier has better effect, while as a value, the larger AUC is, the better the classifier has effect. Therefore, we applied 5-fold CV in IMDAILM, and the result showed that the AUC value was 0.8870. AUPR=0.4040. We plotted its ROC curve of 5-fold CV in Fig.3 .
1) MODEL PARAMETERS
We use the 5-fold cross-validation process to train the parameter α 1 , α 2 , α 3 . Specifically, we increase the three parameters from 0.1 to 1 with a step of 0.1, and select the parameters with the highest AUC value. Experimental results show that when α 1 = 0.1, α 2 = 1, α 3 = 0.5, the highest AUC value is 0.8870. We list some of them in TABLE 1. 
2) CASE STUDIES
MiRNA plays a key role in the development of many diseases. However, the occurrence of disease may also be related to lncRNAs, so we selected three known important diseases related to lncRNA, and performed the method to obtain the top 5 lncRNA and miRNA (see TABLE2). In addition, we also drew the association network diagram of the three diseases and their top 5 lncRNA and miRNA in for better observation (see Fig.4 ). The results of the experiments indicate that these diseases are not only related to lncRNA, but also most likely due to abnormalities in miRNAs.
Cervical cancer is the most common gynecological malignancy, resulting in many deaths in developing countries [31] . It is reported that about 500,000 people are diagnosed with cervical cancer every year [32] . Early cervical cancer is often asymptomatic and asymptomatic, so it is difficult to detect early. Therefore, it is very important to explore the biological mechanism to develop effective treatment strategies. Taking cervical cancer as an example, IMDAILM predicted the first five related miRNAs and lncRNAs. For example, MEG3 can inhibit the growth of cervical cancer tumor by regulating mir-21-5p [33] . Serum PVT1 can accurately distinguish patients with cervical cancer from healthy controls [34] . High expression of HOTAIR is involved in the progression of cervical cancer and may be a potential target for diagnosis and gene therapy [35] .
Glioma is the most common primary tumor of the central nervous system and the most common malignant tumor of the central nervous system, characterized by invasive angiogenesis [36] . Despite the continuous improvement of surgery, radiotherapy, chemotherapy and other treatment methods, the survival period of patients with glioma after diagnosis is only about 12-14 months [37] . Tumor angiogenesis is the main cause of poor therapeutic effect. We applied IMDAILM to glioma and achieved good results. The top 5 miRNAs and lncRNAs related to glioma were listed in the table2, and the predicted top 5 lncRNAs were confirmed in the latest LncRNADisease database and literature. For example, H19 regulates the development of glioma through the derivation of mir-675, and provides an important clue to understand the key role of the functional network of lncRNA+miRNA in glioma [38] . In addition, Gas5 usually inhibits tumor malignancy by down-regulating mir-222, which may be very promising for the treatment of glioma [39] .
Non-small cell lung cancer (NSCLC) is the main form of lung cancer, accounting for about 80% of all lung cancers. It includes adenocarcinoma and squamous cell carcinoma, whose cancer cells grow and divide more slowly and spread and metastasize later than small-cell carcinoma [40] . In recent years, although the clinical and experimental oncology made progress, the prognosis is still very difficult. Increasing evidence suggests that non-coding RNAs (ncRNAs) may be involved in the pathogenesis of NSCLC. Similarly, IMDAILM predicted the first 5 NSCLC-related miRNAs and lncRNAs. For example, the expression of CDKN2B-AS1 (ANRIL) may damage cell proliferation and lead to apoptosis in-vitro or in-vivo [41] , which is related to the survival of NSCLC patients.
B. PERFORMANCE ON PREDICTING miRNA-DISEASE ASSOCIATION
We used IMDAILM to predict the association of miRNAdisease. Specifically, the association data of miRNA and disease in the association matrix NDA were first selected according to HMDD V2.0, and then cross-verified by 5-fold, that is all known miRNA-disease associations were randomly divided into 5 uncrossed sites of equal size. We use one of the parts as a test sample for prediction, and the other four parts of the sample as training data to build a predictive model. This process is repeated 5 times and ends when all samples are predicted once, when α 1 = 0.1, α 2 = 1, α 3 = 0.5, the results showed that the AUC value was 0.8884. The AUC of NCPMDA and RLSMDA were calculated in the same way, and the results were 0.8637 and 0.8415, respectively. The ROC curves of the IMDAILM, NCPMDA and RLSMDA were plotted in Fig.5 .
1) CASE STUDIES
It is well known that miRNA plays a key role in the development of many diseases. It is important to examine the prediction performance of global miRNA-disease, as well as the prediction performance of the method for specific diseases. To further assess the ability of IMDAILM to infer new miRNA-disease associations, we removed all known diseaserelated associations and evaluated the new predictions. We used all known lncRNA+miRNA-disease associations as training data and assessed the potential for predictive associations through IMDAILM. New miRNA-disease associations were sequenced according to the predicted results. To be specific, the top 10 miRNAs related to colon Neoplasms, Lung Neoplasms and Kidney Neoplasms were listed in TABLE 3, 4 and'5. For better observation, we also drew the association network diagram of three diseases and their top 10 predicted miRNAs in Fig.6 .
Colon Neoplasms are the second leading cause of cancer-related death in the United States [42] . Although chemotherapy has important therapeutic value, the only current treatment for colon Neoplasms is surgery. Therefore, it is urgent to find potential biomarkers that are strongly responsive to clinical observation. The researchers confirmed mir-21 by in situ hybridization technique in colon cancer cells [43] with high expression level. In addition, let-7 has potential growth inhibition in human colon cancer tumors and cells [44] . Due to identify more with colon cancer related microRNAs help to accurately assess the clinical results, we carried out a case study of colon tumor using IMDAILM. In the prediction list, 9 of the top 10 predicted miRNAs were confirmed to be associated with colon tumors according to the recent experimental literature. For example, preclinical studies have shown that mir-21 expression is associated with the clinicopathological characteristics of colorectal cancer [45] . The experimental study also found that the expression of mir-20a in colon cancer tissues was significantly higher than that in normal tissues [46] . mir-18a is considered to be a colon cancer suppressor, affecting cell proliferation and anchored independent growth by targeting K-Ras (mRNA) [47] .
Lung cancer is one of the most malignant tumors with the fastest growth in morbidity and mortality and the greatest threat to population health and life. In the past 50 years, many countries have reported a significant increase in the incidence and mortality of lung cancer. About 1.4 million people die of lung cancer each year in China. Recent experimental studies have shown that miRNAs play a key role in the progression of lung cancer. Therefore, we carried out IMDAILM with lung Neoplasms as an example, we verified the top 10 predicted lung Neoplasms-associated miRNAs based on the experimental results. For example, Hsa-mir-195, ranked 1st, has been shown to inhibit tumor growth and it is associated with survival outcomes in a variety of malignancies, including lung cancer [48] . Bozok et al. analyzed the resistance of selected miRNAs on the development of cisplatin resistance, the impact of sexual development found that hsa-mir-15a (ranked 2nd) was one of the most prominent down-regulated miRNAs in Calu1 epidermoid lung cancer cells [49] .
Kidney Neoplasms is a fastest-growing type of cancer, especially among blacks, where more than 80 percent of patients are found to have renal cell carcinoma (RCC). Recent studies have found that mir-34a is often overexpressed in patients with RCC, which plays a key role in slowing the growth of RCC. To identify potential miRNA associations for disease, we performed case studies of renal tumors. Existing experimental literature has shown that 9 of the top 10 potential miRNAs are correctly associated with this important human disease. For example, mir-155, mir-126 and mir-20a were identified in the clear cell type of human renal cell carcinoma (ccRCC), as compared to normal kidney samples [50] , [51] . In addition, mir-145 and mir-146a were found to have over expression of target mRNA and protein expressions that inhibit their stat1 pathway expression in renal tissue.
IV. CONCLUSION
In this study, we integrated the miRNA-disease association network and the lncRNA-disease association network, and then applied a predictive method based on low-rank matrix completion to predict the miRNA-disease association. First, the miRNA-disease association data and the lncRNA-disease association data were obtained from the known database, and then they were integrated to obtain the lncRNA+miRNA-disease association network, which increased the disease-related information and contributed to improve the prediction performance. Then, the mapping network was constructed in the lncRNA+miRNA-disease association, and negative samples were constructed with the invariant nature of the mapping network. Next, the miRNAdisease association prediction was taken as a low-rank matrix completion problem, the lncRNA+miRNA similarity and disease similarity were taken as the edge information, and an alternating gradient descent method was used to solve the problem. We compared IMDAILM with some algorithms with the best performance in the data sets collected from the known miRNA-disease database, and verified the effectiveness of IMDAILM through cross-validation and case study of the collected data sets.
Different from previous studies, we integrated known information of miRNA-disease and lncRNA-disease. Since both miRNA and lncRNA are associated with diseases and they are also correlated. Thus, the fusion of two information will add an additional layer of resource to infer their association with diseases. In practice, our method is indeed better than previous methods with only miRNA-disease information. Compared with other methods, IMDAILM has higher prediction accuracy in global 5-fold CV and single disease 5-fold CV. Not only is it very effective in predicting the association of lncRNA, miRNA and disease, but the accuracy in predicting only the association of miRNA-disease is also higher than other methods. We also found some new miRNAs related to disease for further experimental verification. However, we are fully aware that there are some limitations of our method. firstly, when lncRNA-disease association network and miRNA-disease association network were fused, IMDAILM only considered the relationship between lncRNA and disease, but did not consider the relationship between lncRNA and miRNA, the effect would be better if the relationship between lncRNA and miRNA could be considered. Secondly, it might be better to integrate multiple source information to calculate miRNA-miRNA and lncRNA-lncRNA similarities. In the future, we will also work towards combining multiple prediction models to achieve a more accurate prediction. 
